CAL
ALXN

Capital Analysts LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Analysts LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-650
Closed -$74K – 831
2020
Q3 		$74K Sell
650
-650
-50% -$70.1K 0.01% 354
2020
Q2 		$146K Sell
1,300
-1,274
-49% -$135K 0.02% 244
2020
Q1 		$231K Buy
2,574
+600
+30% +$58.9K 0.03% 198
2019
Q4 		$213K Hold
1,974
– – 0.02% 232
2019
Q3 		$193K Buy
1,974
+57
+3% +$6.42K 0.02% 225
2019
Q2 		$251K Buy
1,917
+148
+8% +$19.1K 0.03% 206
2019
Q1 		$239K Hold
1,769
– – 0.03% 205
2018
Q4 		$172K Hold
1,769
– – 0.02% 209
2018
Q3 		$246K Hold
1,769
– – 0.03% 183
2018
Q2 		$220K Hold
1,769
– – 0.03% 191
2018
Q1 		$197K Buy
+1,769
New +$211K 0.02% 188

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital Analysts LLC's ALXN Position: Q4 2020 in Review

Capital Analysts LLC sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 650 shares — an estimated $74K sold.

Capital Analysts LLC first reported a position in ALXN in Q1 2018 and held it in 11 quarters. The position peaked at $251K in Q2 2019. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Capital Analysts LLC reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 650 Alexion Pharmaceuticals shares in Q4 2020, an estimated $74K.
  • Capital Analysts LLC first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 11 quarters.
  • Capital Analysts LLC's Alexion Pharmaceuticals position peaked at $251K in Q2 2019.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.